세계의 방사성의약품 시장 : 최종사용자별, 방사성 동위원소별, 용도별, 유형별 - 기회 분석 및 산업 예측(2024-2033년)

Radiopharmaceuticals Market By End User, By Radioisotope, By Application, By Type : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 6,180 ￦ 8,632,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 10,860 ￦ 15,170,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계 방사성의약품 시장 규모는 2023년 79억 달러로 평가되며, 2024-2033년 연평균 10.6% 성장해 2033년에는 218억 달러에 달할 것으로 추정됩니다. 방사성의약품은 방사성 동위원소로 알려진 화학 원소의 방사성 버전을 포함하는 의약품입니다. 방사성 동위원소는 방사선의 종류에 따라 다양한 질병의 진단과 치료에 사용됩니다. 그 용도는 뇌, 심장, 신장, 뼈 등 다양한 장기의 검사 및 치료부터 암 및 갑상선 기능 항진증 치료까지 다양합니다. 방사성의약품은 주사 또는 경구 투여를 통해 환자에게 투여되며, 외부 의료기기나 검사를 통해 모니터링 및 분석이 이루어지기도 합니다. 대부분의 국가에서는 방사성의약품의 잠재적 부작용으로부터 환자와 의료진을 보호하기 위해 전문적인 안전 조치를 취하고 있습니다.

방사성의약품 시장은 만성질환의 증가, 기술 발전, 진단 및 치료 시술의 만성질환의 증가, 기술 발전, 진단 및 치료 시술의 용도 확대가 주요 요인으로 작용하고 있습니다. 암, 심혈관 질환, 신경계 질환 등 만성질환의 유병률이 지속적으로 증가함에 따라 효과적인 진단 도구와 표적치료에 대한 수요가 증가하고 있습니다. 정확한 영상 진단과 치료 옵션을 제공할 수 있는 방사성의약품은 이러한 질병과 싸우는 데 있어 귀중한 도구로 점점 더 많이 인식되고 있습니다. 또한 PET 및 SPECT와 같은 영상 진단 기술의 발전으로 진단의 정확성과 효율성이 크게 향상되어 질병을 조기에 발견하고 더 잘 관리할 수 있게 된 것도 시장 성장에 기여하고 있습니다. 또한, 개인 맞춤형 의료 접근법의 등장으로 환자 개개인의 특성과 분자 표적에 따라 맞춤형 치료가 가능해지면서 방사성의약품에 대한 수요를 촉진하고 있습니다. 그러나 방사성의약품의 개발 및 생산 비용이 높아 시장 성장을 저해하는 요인으로 작용하고 있습니다. 여기에는 연구, 임상시험, 제조 공정, 규제 준수와 관련된 비용이 포함됩니다. 또한 방사성의약품의 복잡한 특성으로 인해 전문 인프라와 전문 지식이 필요하기 때문에 경제적 부담은 더욱 커집니다. 반면, 방사성의약품의 연구개발 활동은 영상 진단과 표적치료를 결합한 테라노스틱스(theranostics)와 같은 분야에서의 사용이 검토되고 있어 시장 성장의 기회로 작용하고 있습니다. 방사성의약품 시장은 유형, 용도, 방사성 동위원소, 최종사용자, 지역별로 분류됩니다. 유형별로는 진단용과 치료용으로 시장이 양분됩니다. 용도별로는 암, 순환기, 기타로 분류됩니다. 암 분야는 전립선암, 유방암, 소화기암, 폐암, 뇌종양, 기타로 세분화됩니다. 기타 부문은 다시 신경학적 응용과 기타 응용으로 나뉩니다. 방사성 동위원소 기준으로는 요오드 I, 갈륨 68, 테크네튬 99m, 불소 18, 구리 64, 스트론튬 89, 이트륨 90, 라듐 223, 악티늄 225, 루테튬 177, 구리 67, 테르븀 161, 지르코늄 89, 기타로 세분화됩니다. 최종사용자별로 시장은 병원 및 클리닉, 의료영상센터, 기타로 분류됩니다. 지역별로는 북미(미국, 캐나다), 유럽(독일, 영국, 프랑스, 스페인, 이탈리아, 기타 유럽), 아시아태평양(인도, 중국, 호주, 일본, 한국, 태국, 말레이시아, 인도네시아, 싱가포르, 대만, 기타 아시아태평양), 라틴아메리카(브라질 및 기타 라틴아메리카)에서 조사되고 있습니다. 세계 방사성의약품 시장에서 활동하는 주요 기업으로는 Bayer AG, Cardinal Health, Eli Lilly and Company, Bracco, Isotopia Molecular Imaging Ltd., Actinium Pharmaceuticals, Inc., Novartis AG, Curium Pharma, Nihon Medi-Physics Co. Ltd., Jubilant Pharmova Limited, Eckert & Ziegler, NorthStar Radioisotopes, The State Atomic Energy Corporation ROSATOM, SOFIE, Lantheus, Telix Pharmaceuticals Limited, Clarity Pharmaceuticals, Fusion Pharmaceuticals Inc., PRECIRIX, ITM Isotope Technologies Munich SE, GE Healthcare, South African Nuclear Energy Corporation (Necsa), and Eczacibasi 등이 있습니다. 이 시장에서 활동하는 주요 기업들은 제품 포트폴리오를 확장하기 위한 주요 전략으로 계약, 인수, 사업 확장, 임상시험, 제품 승인, 제품 업그레이드, 계약, 제품 개발, 제휴, 지리적 확장, 합작 투자, 확장 등을 채택하고 있습니다.

이해관계자를 위한 주요 이점

• 이 보고서는 2023-2033년 방사성의약품 시장 분석의 시장 부문, 현재 동향, 추정 동향 및 역학을 정량적으로 분석하여 일반적인 방사성의약품 시장 기회를 식별합니다.
• 시장 촉진요인, 시장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급업체와 공급업체의 네트워크를 강화할 수 있도록 구매자와 공급업체의 힘을 강조합니다.
• 방사성의약품 시장의 세분화를 자세히 분석하여 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가를 세계 시장에 대한 수익 기여도에 따라 매핑하고 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고, 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계 방사성의약품 시장 동향, 주요 기업, 시장 부문, 응용 분야, 시장 성장 전략에 대한 분석이 포함되어 있습니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
    • 만성질환 증가
    • 주요 기업에 의한 전략 채용 증가
    • 연구개발 활동 증가
  • 성장 억제요인
    • 방사성의약품 개발과 도입의 높은 비용
  • 기회
    • 파이프라인 제품 증가

제4장 방사성의약품 시장 : 최종사용자별

• 개요
• 병원·클리닉
• 의료 영상 센터
• 기타

제5장 방사성의약품 시장 : 방사성 동위원소별

• 개요
• 테크네튬 99m
• 갈륨 68
• 요오드 I
• 불소 18
• 구리 64
• 스트론튬 89
• 이트륨 90
• 라듐 223
• 액티늄 225
• 루테튬 177
• 구리 67
• 테르븀 161
• 지르코늄 89
• 기타

제6장 방사성의약품 시장 : 용도별

• 개요
• 암
  • 암 방사성의약품 시장 : 유형별
• 순환기
• 기타
  • 기타 방사성의약품 시장 : 유형별

제7장 방사성의약품 시장 : 유형별

• 개요
• 진단용
• 치료용

제8장 방사성의약품 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
  • 말레이시아
  • 인도네시아
  • 싱가포르
  • 대만
  • 기타
• 라틴아메리카, 중동 및 아프리카
  • 브라질
  • 기타

제9장 경쟁 상황

• 소개
• 주요 성공 전략
• 주요 10개사 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제10장 기업 개요

• Bayer AG
• Cardinal Health
• Curium Pharma
• Eli Lilly and Company
• Jubilant Pharmova Limited
• Lantheus
• ITM Isotope Technologies Munich SE
• Telix Pharmaceuticals Limited
• Eckert & Ziegler
• Bracco
• South African Nuclear Energy Corporation(NECSA)
• NorthStar Medical Radioisotopes
• The State Atomic Energy Corporation ROSATOM
• SOFIE
• Isotopia Molecular Imaging
• Fusion Pharmaceuticals Inc.
• Clarity Pharmaceuticals
• Actinium Pharmaceuticals, Inc.
• PRECIRIX
• Novartis AG
• Nihon Medi-Physics Co. Ltd
• GE Healthcare
• Eczacibasi

ksm

영문 목차

영문목차

The radiopharmaceuticals market was valued at $7.9 billion in 2023 and is estimated to reach $21.8 billion by 2033, exhibiting a CAGR of 10.6% from 2024 to 2033. Radiopharmaceuticals are medications that include radioactive versions of chemical elements known as radioisotopes. Depending on the type of radiation they emit, radioisotopes can be used to diagnose or treat a variety of medical diseases. Their uses range from examining and treating various organs, including the brain, heart, kidney, and bone, to the treatment of cancer and hyperthyroidism. Radiopharmaceuticals are administered to patients via injection or orally, and they may be monitored and analyzed using external medical equipment and testing. Most nations have specialized safety measures in place to safeguard patients and health workers from the potential harmful effects of these pharmaceuticals. The radiopharmaceuticals market is primarily driven by the increase in prevalence of chronic diseases, rise in technological advancements, and growth in applications in diagnostic and therapeutic procedures. As the prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions continues to rise, there is a growing demand for effective diagnostic tools and targeted treatments. Radiopharmaceuticals, with their ability to provide precise imaging and therapeutic options, are increasingly recognized as valuable tools in the fight against these diseases. In addition, advancements in imaging techniques such as PET and SPECT have significantly improved the accuracy and efficiency of diagnosis, enabling early detection and better management of diseases propels the market growth. Additionally, the emergence of personalized medicine approaches has fueled the demand for radiopharmaceuticals, as they allow for tailored treatments on the basis of individual patient characteristics and molecular targets. However, the high cost associated with the development and production of radiopharmaceuticals can be prohibitive, thus hindering the market growth. This includes expenses related to research, clinical trials, and manufacturing processes, and regulatory compliance. The complex nature of radiopharmaceuticals also requires specialized infrastructure and expertise, further adding to the financial burden. In contrast, ongoing R&D activities for radiopharmaceuticals are increasingly being explored for use in areas such as theranostics, which involves combining diagnostic imaging with targeted therapy that provides lucrative opportunities for the market growth. The radiopharmaceuticals market is segmented on the basis of type, application, radioisotope, end user, and region. On the basis of type, the market is bifurcated into diagnostic, and therapeutic. On the basis of application, the market is classified into cancer, cardiology and others. The cancer segment is further classified into prostate cancer, breast cancer, gastrointestinal cancer, lung cancer, brain tumors, and others. The others segment further bifurcated into Neurological Applications and other applications. On the basis of radioisotope, the market is classified into Iodine I, Gallium 68, Technetium 99m, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, and others. On the basis of end user, the market is categorized into hospitals and clinics, medical imaging centers, and others. On the basis of region, the market is studied across North America (U.S. and Canada), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, Thailand, Malaysia, Indonesia, Singapore, Taiwan, Province Of China, and Rest of Asia-Pacific), and LAMEA (Brazil and Rest of LAMEA). Major key players that operate in the global radiopharmaceuticals market are Bayer AG, Cardinal Health, Eli Lilly and Company, Bracco, Isotopia Molecular Imaging Ltd., Actinium Pharmaceuticals, Inc., Novartis AG, Curium Pharma, Nihon Medi-Physics Co. Ltd., Jubilant Pharmova Limited, Eckert & Ziegler, NorthStar Radioisotopes, The State Atomic Energy Corporation ROSATOM, SOFIE, Lantheus, Telix Pharmaceuticals Limited, Clarity Pharmaceuticals, Fusion Pharmaceuticals Inc., PRECIRIX, ITM Isotope Technologies Munich SE, GE Healthcare, South African Nuclear Energy Corporation (Necsa), and Eczacibasi. Key players operating in the market have adopted agreement, acquisition, expansion, clinical trial, product approval, product upgrade, contract, product development, collaboration, geographical expansion, joint venture, and expansion, as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the radiopharmaceuticals market analysis from 2023 to 2033 to identify the prevailing radiopharmaceuticals market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global radiopharmaceuticals market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
• Patient/epidemiology data at country, region, global level
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By End User

• Hospitals and Clinics
• Medical Imaging Centers
• Others

By Radioisotope

• Technetium 99m
• Gallium 68
• Iodine I
• Fluorine 18
• Copper 64
• Strontium 89
• Yttrium 90
• Radium 223
• Actinium 225
• Lutetium 177
• Copper 67
• Terbium 161
• Zirconium 89
• Others

By Application

• Cancer
  • Type
  • Prostate Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Lung Cancer
  • Brain Tumors
  • Others
• Cardiology
• Others
  • Type
  • Neurological Applications
  • Other Applications

By Type

• Diagnostic
• Therapeutic

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • Singapore
  • Taiwan, Province Of China
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Rest of LAMEA

Key Market Players:

• Cardinal Health
• Eli Lilly and Company
• Novartis AG
• Jubilant Pharmova Limited
• The State Atomic Energy Corporation ROSATOM
• SOFIE
• Telix Pharmaceuticals Limited
• Clarity Pharmaceuticals
• PRECIRIX
• NorthStar Medical Radioisotopes
• South African Nuclear Energy Corporation (Necsa)
• Bayer AG
• Bracco
• Curium Pharma
• Eckert & Ziegler
• Lantheus
• Nihon Medi-Physics Co. Ltd
• Isotopia Molecular Imaging
• ITM Isotope Technologies Munich SE
• GE Healthcare
• Actinium Pharmaceuticals, Inc.
• Fusion Pharmaceuticals Inc.
• Eczacibasi

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate low threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. High intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in prevalence of chronic diseases
    • 3.4.1.2. Rise in adoption of strategies by key players
    • 3.4.1.3. Rise in R&D activities
  • 3.4.2. Restraints
    • 3.4.2.1. High cost of development and implementation of radiopharmaceuticals
  • 3.4.3. Opportunities
    • 3.4.3.1. Rise in number of pipeline products

CHAPTER 4: RADIOPHARMACEUTICALS MARKET, BY END USER

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Hospitals and Clinics
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Medical Imaging Centers
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Others
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Technetium 99m
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Gallium 68
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Iodine I
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Fluorine 18
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
• 5.6. Copper 64
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country
• 5.7. Strontium 89
  • 5.7.1. Key market trends, growth factors and opportunities
  • 5.7.2. Market size and forecast, by region
  • 5.7.3. Market share analysis by country
• 5.8. Yttrium 90
  • 5.8.1. Key market trends, growth factors and opportunities
  • 5.8.2. Market size and forecast, by region
  • 5.8.3. Market share analysis by country
• 5.9. Radium 223
  • 5.9.1. Key market trends, growth factors and opportunities
  • 5.9.2. Market size and forecast, by region
  • 5.9.3. Market share analysis by country
• 5.10. Actinium 225
  • 5.10.1. Key market trends, growth factors and opportunities
  • 5.10.2. Market size and forecast, by region
  • 5.10.3. Market share analysis by country
• 5.11. Lutetium 177
  • 5.11.1. Key market trends, growth factors and opportunities
  • 5.11.2. Market size and forecast, by region
  • 5.11.3. Market share analysis by country
• 5.12. Copper 67
  • 5.12.1. Key market trends, growth factors and opportunities
  • 5.12.2. Market size and forecast, by region
  • 5.12.3. Market share analysis by country
• 5.13. Terbium 161
  • 5.13.1. Key market trends, growth factors and opportunities
  • 5.13.2. Market size and forecast, by region
  • 5.13.3. Market share analysis by country
• 5.14. Zirconium 89
  • 5.14.1. Key market trends, growth factors and opportunities
  • 5.14.2. Market size and forecast, by region
  • 5.14.3. Market share analysis by country
• 5.15. Others
  • 5.15.1. Key market trends, growth factors and opportunities
  • 5.15.2. Market size and forecast, by region
  • 5.15.3. Market share analysis by country

CHAPTER 6: RADIOPHARMACEUTICALS MARKET, BY APPLICATION

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Cancer
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
  • 6.2.4. Cancer Radiopharmaceuticals Market by Type
• 6.3. Cardiology
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Others
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country
  • 6.4.4. Others Radiopharmaceuticals Market by Type

CHAPTER 7: RADIOPHARMACEUTICALS MARKET, BY TYPE

• 7.1. Overview
  • 7.1.1. Market size and forecast
• 7.2. Diagnostic
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by region
  • 7.2.3. Market share analysis by country
• 7.3. Therapeutic
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by region
  • 7.3.3. Market share analysis by country

CHAPTER 8: RADIOPHARMACEUTICALS MARKET, BY REGION

• 8.1. Overview
  • 8.1.1. Market size and forecast By Region
• 8.2. North America
  • 8.2.1. Key market trends, growth factors and opportunities
  • 8.2.2. Market size and forecast, by End User
  • 8.2.3. Market size and forecast, by Radioisotope
  • 8.2.4. Market size and forecast, by Application
  • 8.2.5. Market size and forecast, by Type
  • 8.2.6. Market size and forecast, by country
    • 8.2.6.1. U.S.
    • 8.2.6.1.1. Market size and forecast, by End User
    • 8.2.6.1.2. Market size and forecast, by Radioisotope
    • 8.2.6.1.3. Market size and forecast, by Application
    • 8.2.6.1.4. Market size and forecast, by Type
    • 8.2.6.2. Canada
    • 8.2.6.2.1. Market size and forecast, by End User
    • 8.2.6.2.2. Market size and forecast, by Radioisotope
    • 8.2.6.2.3. Market size and forecast, by Application
    • 8.2.6.2.4. Market size and forecast, by Type
• 8.3. Europe
  • 8.3.1. Key market trends, growth factors and opportunities
  • 8.3.2. Market size and forecast, by End User
  • 8.3.3. Market size and forecast, by Radioisotope
  • 8.3.4. Market size and forecast, by Application
  • 8.3.5. Market size and forecast, by Type
  • 8.3.6. Market size and forecast, by country
    • 8.3.6.1. Germany
    • 8.3.6.1.1. Market size and forecast, by End User
    • 8.3.6.1.2. Market size and forecast, by Radioisotope
    • 8.3.6.1.3. Market size and forecast, by Application
    • 8.3.6.1.4. Market size and forecast, by Type
    • 8.3.6.2. France
    • 8.3.6.2.1. Market size and forecast, by End User
    • 8.3.6.2.2. Market size and forecast, by Radioisotope
    • 8.3.6.2.3. Market size and forecast, by Application
    • 8.3.6.2.4. Market size and forecast, by Type
    • 8.3.6.3. UK
    • 8.3.6.3.1. Market size and forecast, by End User
    • 8.3.6.3.2. Market size and forecast, by Radioisotope
    • 8.3.6.3.3. Market size and forecast, by Application
    • 8.3.6.3.4. Market size and forecast, by Type
    • 8.3.6.4. Italy
    • 8.3.6.4.1. Market size and forecast, by End User
    • 8.3.6.4.2. Market size and forecast, by Radioisotope
    • 8.3.6.4.3. Market size and forecast, by Application
    • 8.3.6.4.4. Market size and forecast, by Type
    • 8.3.6.5. Spain
    • 8.3.6.5.1. Market size and forecast, by End User
    • 8.3.6.5.2. Market size and forecast, by Radioisotope
    • 8.3.6.5.3. Market size and forecast, by Application
    • 8.3.6.5.4. Market size and forecast, by Type
    • 8.3.6.6. Rest of Europe
    • 8.3.6.6.1. Market size and forecast, by End User
    • 8.3.6.6.2. Market size and forecast, by Radioisotope
    • 8.3.6.6.3. Market size and forecast, by Application
    • 8.3.6.6.4. Market size and forecast, by Type
• 8.4. Asia-Pacific
  • 8.4.1. Key market trends, growth factors and opportunities
  • 8.4.2. Market size and forecast, by End User
  • 8.4.3. Market size and forecast, by Radioisotope
  • 8.4.4. Market size and forecast, by Application
  • 8.4.5. Market size and forecast, by Type
  • 8.4.6. Market size and forecast, by country
    • 8.4.6.1. Japan
    • 8.4.6.1.1. Market size and forecast, by End User
    • 8.4.6.1.2. Market size and forecast, by Radioisotope
    • 8.4.6.1.3. Market size and forecast, by Application
    • 8.4.6.1.4. Market size and forecast, by Type
    • 8.4.6.2. China
    • 8.4.6.2.1. Market size and forecast, by End User
    • 8.4.6.2.2. Market size and forecast, by Radioisotope
    • 8.4.6.2.3. Market size and forecast, by Application
    • 8.4.6.2.4. Market size and forecast, by Type
    • 8.4.6.3. India
    • 8.4.6.3.1. Market size and forecast, by End User
    • 8.4.6.3.2. Market size and forecast, by Radioisotope
    • 8.4.6.3.3. Market size and forecast, by Application
    • 8.4.6.3.4. Market size and forecast, by Type
    • 8.4.6.4. Australia
    • 8.4.6.4.1. Market size and forecast, by End User
    • 8.4.6.4.2. Market size and forecast, by Radioisotope
    • 8.4.6.4.3. Market size and forecast, by Application
    • 8.4.6.4.4. Market size and forecast, by Type
    • 8.4.6.5. South Korea
    • 8.4.6.5.1. Market size and forecast, by End User
    • 8.4.6.5.2. Market size and forecast, by Radioisotope
    • 8.4.6.5.3. Market size and forecast, by Application
    • 8.4.6.5.4. Market size and forecast, by Type
    • 8.4.6.6. Thailand
    • 8.4.6.6.1. Market size and forecast, by End User
    • 8.4.6.6.2. Market size and forecast, by Radioisotope
    • 8.4.6.6.3. Market size and forecast, by Application
    • 8.4.6.6.4. Market size and forecast, by Type
    • 8.4.6.7. Malaysia
    • 8.4.6.7.1. Market size and forecast, by End User
    • 8.4.6.7.2. Market size and forecast, by Radioisotope
    • 8.4.6.7.3. Market size and forecast, by Application
    • 8.4.6.7.4. Market size and forecast, by Type
    • 8.4.6.8. Indonesia
    • 8.4.6.8.1. Market size and forecast, by End User
    • 8.4.6.8.2. Market size and forecast, by Radioisotope
    • 8.4.6.8.3. Market size and forecast, by Application
    • 8.4.6.8.4. Market size and forecast, by Type
    • 8.4.6.9. Singapore
    • 8.4.6.9.1. Market size and forecast, by End User
    • 8.4.6.9.2. Market size and forecast, by Radioisotope
    • 8.4.6.9.3. Market size and forecast, by Application
    • 8.4.6.9.4. Market size and forecast, by Type
    • 8.4.6.10. Taiwan, Province Of China
    • 8.4.6.10.1. Market size and forecast, by End User
    • 8.4.6.10.2. Market size and forecast, by Radioisotope
    • 8.4.6.10.3. Market size and forecast, by Application
    • 8.4.6.10.4. Market size and forecast, by Type
    • 8.4.6.11. Rest of Asia-Pacific
    • 8.4.6.11.1. Market size and forecast, by End User
    • 8.4.6.11.2. Market size and forecast, by Radioisotope
    • 8.4.6.11.3. Market size and forecast, by Application
    • 8.4.6.11.4. Market size and forecast, by Type
• 8.5. LAMEA
  • 8.5.1. Key market trends, growth factors and opportunities
  • 8.5.2. Market size and forecast, by End User
  • 8.5.3. Market size and forecast, by Radioisotope
  • 8.5.4. Market size and forecast, by Application
  • 8.5.5. Market size and forecast, by Type
  • 8.5.6. Market size and forecast, by country
    • 8.5.6.1. Brazil
    • 8.5.6.1.1. Market size and forecast, by End User
    • 8.5.6.1.2. Market size and forecast, by Radioisotope
    • 8.5.6.1.3. Market size and forecast, by Application
    • 8.5.6.1.4. Market size and forecast, by Type
    • 8.5.6.2. Rest of LAMEA
    • 8.5.6.2.1. Market size and forecast, by End User
    • 8.5.6.2.2. Market size and forecast, by Radioisotope
    • 8.5.6.2.3. Market size and forecast, by Application
    • 8.5.6.2.4. Market size and forecast, by Type

CHAPTER 9: COMPETITIVE LANDSCAPE

• 9.1. Introduction
• 9.2. Top winning strategies
• 9.3. Product mapping of top 10 player
• 9.4. Competitive dashboard
• 9.5. Competitive heatmap
• 9.6. Top player positioning, 2023

CHAPTER 10: COMPANY PROFILES

• 10.1. Bayer AG
  • 10.1.1. Company overview
  • 10.1.2. Key executives
  • 10.1.3. Company snapshot
  • 10.1.4. Operating business segments
  • 10.1.5. Product portfolio
  • 10.1.6. Business performance
  • 10.1.7. Key strategic moves and developments
• 10.2. Cardinal Health
  • 10.2.1. Company overview
  • 10.2.2. Key executives
  • 10.2.3. Company snapshot
  • 10.2.4. Operating business segments
  • 10.2.5. Product portfolio
  • 10.2.6. Business performance
  • 10.2.7. Key strategic moves and developments
• 10.3. Curium Pharma
  • 10.3.1. Company overview
  • 10.3.2. Key executives
  • 10.3.3. Company snapshot
  • 10.3.4. Operating business segments
  • 10.3.5. Product portfolio
  • 10.3.6. Key strategic moves and developments
• 10.4. Eli Lilly and Company
  • 10.4.1. Company overview
  • 10.4.2. Key executives
  • 10.4.3. Company snapshot
  • 10.4.4. Operating business segments
  • 10.4.5. Product portfolio
  • 10.4.6. Business performance
  • 10.4.7. Key strategic moves and developments
• 10.5. Jubilant Pharmova Limited
  • 10.5.1. Company overview
  • 10.5.2. Key executives
  • 10.5.3. Company snapshot
  • 10.5.4. Operating business segments
  • 10.5.5. Product portfolio
  • 10.5.6. Business performance
  • 10.5.7. Key strategic moves and developments
• 10.6. Lantheus
  • 10.6.1. Company overview
  • 10.6.2. Key executives
  • 10.6.3. Company snapshot
  • 10.6.4. Operating business segments
  • 10.6.5. Product portfolio
  • 10.6.6. Business performance
  • 10.6.7. Key strategic moves and developments
• 10.7. ITM Isotope Technologies Munich SE
  • 10.7.1. Company overview
  • 10.7.2. Key executives
  • 10.7.3. Company snapshot
  • 10.7.4. Operating business segments
  • 10.7.5. Product portfolio
  • 10.7.6. Key strategic moves and developments
• 10.8. Telix Pharmaceuticals Limited
  • 10.8.1. Company overview
  • 10.8.2. Key executives
  • 10.8.3. Company snapshot
  • 10.8.4. Operating business segments
  • 10.8.5. Product portfolio
  • 10.8.6. Business performance
  • 10.8.7. Key strategic moves and developments
• 10.9. Eckert & Ziegler
  • 10.9.1. Company overview
  • 10.9.2. Key executives
  • 10.9.3. Company snapshot
  • 10.9.4. Operating business segments
  • 10.9.5. Product portfolio
  • 10.9.6. Business performance
  • 10.9.7. Key strategic moves and developments
• 10.10. Bracco
  • 10.10.1. Company overview
  • 10.10.2. Key executives
  • 10.10.3. Company snapshot
  • 10.10.4. Operating business segments
  • 10.10.5. Product portfolio
  • 10.10.6. Key strategic moves and developments
• 10.11. South African Nuclear Energy Corporation (NECSA)
  • 10.11.1. Company overview
  • 10.11.2. Key executives
  • 10.11.3. Company snapshot
  • 10.11.4. Operating business segments
  • 10.11.5. Product portfolio
  • 10.11.6. Business performance
  • 10.11.7. Key strategic moves and developments
• 10.12. NorthStar Medical Radioisotopes
  • 10.12.1. Company overview
  • 10.12.2. Key executives
  • 10.12.3. Company snapshot
  • 10.12.4. Operating business segments
  • 10.12.5. Product portfolio
  • 10.12.6. Key strategic moves and developments
• 10.13. The State Atomic Energy Corporation ROSATOM
  • 10.13.1. Company overview
  • 10.13.2. Key executives
  • 10.13.3. Company snapshot
  • 10.13.4. Operating business segments
  • 10.13.5. Product portfolio
  • 10.13.6. Key strategic moves and developments
• 10.14. SOFIE
  • 10.14.1. Company overview
  • 10.14.2. Key executives
  • 10.14.3. Company snapshot
  • 10.14.4. Operating business segments
  • 10.14.5. Product portfolio
  • 10.14.6. Key strategic moves and developments
• 10.15. Isotopia Molecular Imaging
  • 10.15.1. Company overview
  • 10.15.2. Key executives
  • 10.15.3. Company snapshot
  • 10.15.4. Operating business segments
  • 10.15.5. Product portfolio
  • 10.15.6. Key strategic moves and developments
• 10.16. Fusion Pharmaceuticals Inc.
  • 10.16.1. Company overview
  • 10.16.2. Key executives
  • 10.16.3. Company snapshot
  • 10.16.4. Operating business segments
  • 10.16.5. Product portfolio
  • 10.16.6. Key strategic moves and developments
• 10.17. Clarity Pharmaceuticals
  • 10.17.1. Company overview
  • 10.17.2. Key executives
  • 10.17.3. Company snapshot
  • 10.17.4. Operating business segments
  • 10.17.5. Product portfolio
  • 10.17.6. Key strategic moves and developments
• 10.18. Actinium Pharmaceuticals, Inc.
  • 10.18.1. Company overview
  • 10.18.2. Key executives
  • 10.18.3. Company snapshot
  • 10.18.4. Operating business segments
  • 10.18.5. Product portfolio
  • 10.18.6. Business performance
  • 10.18.7. Key strategic moves and developments
• 10.19. PRECIRIX
  • 10.19.1. Company overview
  • 10.19.2. Key executives
  • 10.19.3. Company snapshot
  • 10.19.4. Operating business segments
  • 10.19.5. Product portfolio
  • 10.19.6. Key strategic moves and developments
• 10.20. Novartis AG
  • 10.20.1. Company overview
  • 10.20.2. Key executives
  • 10.20.3. Company snapshot
  • 10.20.4. Operating business segments
  • 10.20.5. Product portfolio
  • 10.20.6. Business performance
  • 10.20.7. Key strategic moves and developments
• 10.21. Nihon Medi-Physics Co. Ltd
  • 10.21.1. Company overview
  • 10.21.2. Key executives
  • 10.21.3. Company snapshot
  • 10.21.4. Operating business segments
  • 10.21.5. Product portfolio
• 10.22. GE Healthcare
  • 10.22.1. Company overview
  • 10.22.2. Key executives
  • 10.22.3. Company snapshot
  • 10.22.4. Operating business segments
  • 10.22.5. Product portfolio
  • 10.22.6. Business performance
  • 10.22.7. Key strategic moves and developments
• 10.23. Eczacibasi
  • 10.23.1. Company overview
  • 10.23.2. Key executives
  • 10.23.3. Company snapshot
  • 10.23.4. Operating business segments
  • 10.23.5. Product portfolio
  • 10.23.6. Business performance
  • 10.23.7. Key strategic moves and developments

관련자료